151 related articles for article (PubMed ID: 9093703)
1. Dose intensity for bolus versus infusion chemotherapy administration: review of the literature for 27 anti-neoplastic agents.
Lokich J; Anderson N
Ann Oncol; 1997 Jan; 8(1):15-25. PubMed ID: 9093703
[TBL] [Abstract][Full Text] [Related]
2. Comparison of costs for infusion versus bolus chemotherapy administration: analysis of five standard chemotherapy regimens in three common tumors--Part one. Model projections for cost based on charges.
Lokich JJ; Moore CL; Anderson NR
Cancer; 1996 Jul; 78(2):294-9. PubMed ID: 8674006
[TBL] [Abstract][Full Text] [Related]
3. Controversial issues in 5-fluorouracil infusion use. Dose intensity, treatment duration, and cost comparisons.
Anderson N; Lokich J
Cancer; 1992 Aug; 70(4 Suppl):998-1002. PubMed ID: 1638471
[TBL] [Abstract][Full Text] [Related]
4. 5-methyltetrahydrofolate for biochemical modulation of fluorouracil (FU) in patients with advanced colorectal cancer: a randomized phase I-II study of two different FU administration schedules.
Hejna M; Kornek GV; Raderer M; Valencak J; Weinländer G; Fiebiger W; Miholic J; Scheithauer W
Ann Oncol; 1998 Dec; 9(12):1309-14. PubMed ID: 9932161
[TBL] [Abstract][Full Text] [Related]
5. An EORTC phase I study of epirubicin in combination with fixed doses of cyclophosphamide and infusional 5-fu (CEF-infu) as primary treatment of large operable or locally advanced/inflammatory breast cancer.
Bonnefoi H; Biganzoli L; Cufer T; Mauriac L; Hamilton A; Schaefer P; Piccart M
Breast Cancer Res Treat; 2001 Nov; 70(1):55-63. PubMed ID: 11768362
[TBL] [Abstract][Full Text] [Related]
6. Infusional carboplatin. Phase I studies of 5-day and 14-day infusions.
Lokich J; Anderson N; Bern M; Zipli T; Gonsalves L; Moore C
Cancer; 1991 Jul; 68(1):68-71. PubMed ID: 2049755
[TBL] [Abstract][Full Text] [Related]
7. Cancer chemotherapy and infusional scheduling.
Anderson N; Lokich JJ
Oncology (Williston Park); 1994 May; 8(5):99-111; discussion 111, 115-6. PubMed ID: 8025010
[TBL] [Abstract][Full Text] [Related]
8. Investigation of the comparative toxicity of 5-FU bolus versus 5-FU continuous infusion circadian chemotherapy with concurrent radiation therapy in locally advanced rectal cancer.
Thrall MM; Wood P; King V; Rivera W; Hrushesky W
Int J Radiat Oncol Biol Phys; 2000 Mar; 46(4):873-81. PubMed ID: 10705008
[TBL] [Abstract][Full Text] [Related]
9. Infusional 5-FU for advanced colorectal cancer.
Lokich J
J Infus Chemother; 1995; 5(4):208-11. PubMed ID: 8934730
[TBL] [Abstract][Full Text] [Related]
10. Phase-I dose escalation and sequencing study of docetaxel and continuous infusion topotecan in patients with advanced malignancies.
Posey JA; Wang H; Hamilton J; Delgrosso A; Zhang R; Freda T; Zamboni WC
Cancer Chemother Pharmacol; 2005 Aug; 56(2):182-8. PubMed ID: 15838660
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel by 72-hour continuous infusion followed by bolus intravenous ifosfamide or epirubicin: results of two phase I studies.
Miglietta L; Marenghi C; Nizzo R; Foglia G; Ragni N; Boccardo F
Oncology; 2001; 60(2):116-22. PubMed ID: 11244325
[TBL] [Abstract][Full Text] [Related]
12. Phase I clinical trial of weekly combined topotecan and irinotecan.
Lokich J
Am J Clin Oncol; 2001 Aug; 24(4):336-40. PubMed ID: 11474256
[TBL] [Abstract][Full Text] [Related]
13. Alternate dosing schedules for topotecan in the treatment of recurrent ovarian cancer.
Morris R; Munkarah A
Oncologist; 2002; 7 Suppl 5():29-35. PubMed ID: 12324631
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of continuous infusion 9-aminocamptothecin in patients with advanced solid tumors: 21-day infusion is an active well-tolerated regimen.
Sewak S; Sorich J; O'Leary J
Anticancer Drugs; 2006 Jun; 17(5):571-9. PubMed ID: 16702815
[TBL] [Abstract][Full Text] [Related]
15. Continuous delivery of venous 5-fluorouracil and arterial 5-fluorodeoxyuridine for hepatic metastases from colorectal cancer: feasibility and tolerance in a randomized phase II trial comparing flat versus chronomodulated infusion.
Focan C; Levi F; Kreutz F; Focan-Henrard D; Lobelle JP; Adam R; Dallemagne B; Jehaes C; Markiewicz S; Weerts J; Bismuth H; Jasmin C; Misset JL
Anticancer Drugs; 1999 Apr; 10(4):385-92. PubMed ID: 10378673
[TBL] [Abstract][Full Text] [Related]
16. Regional and systemic therapies for advanced colorectal carcinoma: randomized clinical trial results.
Benson AB
Oncology (Williston Park); 1998 Oct; 12(10 Suppl 7):28-34. PubMed ID: 9830622
[TBL] [Abstract][Full Text] [Related]
17. Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study.
Zalupski M; Metch B; Balcerzak S; Fletcher WS; Chapman R; Bonnet JD; Weiss GR; Ryan J; Benjamin RS; Baker LH
J Natl Cancer Inst; 1991 Jul; 83(13):926-32. PubMed ID: 2067035
[TBL] [Abstract][Full Text] [Related]
18. Role of fluoropyrimidine Schedule and (6R,S)leucovorin dose in a preclinical animal model of colorectal carcinoma.
Cao S; Frank C; Rustum YM
J Natl Cancer Inst; 1996 Apr; 88(7):430-6. PubMed ID: 8618234
[TBL] [Abstract][Full Text] [Related]
19. Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer.
Hansen RM; Ryan L; Anderson T; Krzywda B; Quebbeman E; Benson A; Haller DG; Tormey DC
J Natl Cancer Inst; 1996 May; 88(10):668-74. PubMed ID: 8627643
[TBL] [Abstract][Full Text] [Related]
20. Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B study.
Lilenbaum RC; Miller AA; Batist G; Bernard S; Hollis DR; Rosner GL; Egorin MJ; Schilsky RL; Ratain MJ
J Clin Oncol; 1998 Oct; 16(10):3302-9. PubMed ID: 9779705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
